Strata Critical Medical, Inc.(SRTA)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
Consider higher Upturn Star rating
BUY for 4 days
PROFIT SINCE LAST BUY
-8.47% ▼
LAST CLOSE
$5.51
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for SRTA

11/13/2026: SRTA (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Strata Critical Medical, Inc. is a specialized healthcare logistics and clinical services provider, having recently pivoted from its legacy passenger air mobility business. The company's primary strength lies in its integrated 'One Call' model, which streamlines complex transplant logistics and provides critical perfusion staffing to hospitals nationwide. Growth is driven by the scaling of its specialized clinical service lines and increasing reliance by healthcare systems on outsourced medical services. Key risks include operational execution in a time-sensitive environment and potential competitive pressures from larger hospital service providers. The stock is currently best suited for growth-oriented investors who monitor the adoption rate of the company's integrated medical solutions.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company is in an early-stage growth phase following its transformation into a specialized healthcare services provider.
Momentum investorMixed fitMomentum fit is conditional on a sustained positive trend in adoption of its integrated transplant solutions.
Value investorWeak fitThe company's current valuation and growth-oriented model may not align with traditional value metrics.
Dividend investorWeak fitThe company does not currently pay dividends, focusing instead on scaling its operations.
Low-risk investorWeak fitThe company's small-cap status and recent business model pivot involve volatility and operational risk.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighAs a small-cap stock with a recent business model pivot, shares may experience significant price fluctuations.
Valuation riskMediumValuation is sensitive to future growth projections in the transplant services sector.
Competition risk (healthcare services)Medium / highThe company faces established competitors in medical transportation and clinical staffing.
Business qualityMediumThe long-term franchise quality is currently being established following the transition to the medical services sector.
Dividend incomeLow / noneInvestors should not expect dividend income at the current stage of the company's growth.
Execution riskMedium / highSuccessfully integrating and scaling clinical services across a national footprint is operationally demanding.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 492.15M USD
Price to earnings Ratio -
1Y Target Price 9.62
Price to earnings Ratio -
1Y Target Price 9.62
Volume (30-day avg) 1.1M shares
Beta 2.56
52 Weeks Range 3.95 - 6.50
Updated Date 11/14/2026
52 Weeks Range 3.95 - 6.50
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.24

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Care Facilities

BUY participation
88.9%
Active BUY / eligible
8 / 9
30-Day BUY Count Change
+6

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -52.22%
Avg. Invested days 24
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
SRTA receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
SRTA has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and strong ownership. In FY2025 versus FY2024, strong earnings growth (+251.4%) and strong profitability (net margin 21.0%) are partially offset by weak cash generation (FCF margin -30.4%), negative revenue growth (-20.7%).

Financial Health Rating

★★★★★
SRTA's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 32.7%). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is SRTA's strongest growth driver at +251.4% FY2025 versus FY2024 (strong, 5 stars). By comparison, while revenue growth (-20.7%, negative) and free-cash-flow growth (-68.7%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 74.9% and approximately 65.8% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 14.28% supports management-shareholder alignment.

Top 5 Institutional Investors

Third Point, LLC 5.60%
Becker Drapkin Management, L.P. 5.48%
BlackRock Inc 5.41%
Arnhold & S. Bleichroeder Advisers, LLC 5.18%
Royce & Associates, LP 3.51%

Unit Economics (Per $1K Revenue)

★★★★★
SRTA generates approximately $209 of gross profit, $-113 of operating income, and $-304 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and solid capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 306.06%

Quantitative Style Profile

★★★★★
SRTA has a liquid profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
LogisticsOrgan transport, transplant team logistics, and organ placement services.Revenue is earned by providing essential, time-sensitive transport services for the transplant industry.
ClinicalNRP, organ preservation, cardiac perfusion, and ECMO services.Revenue is earned by placing highly specialized medical professionals and equipment in hospitals.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-11-03
When Before Market
Estimate 0.01
Actual -0.05

Profitability

Profit Margin -8.84%
Operating Margin (TTM) -4.67%

Management Effectiveness

Return on Assets (TTM) -2.47%
Return on Equity (TTM) -7.55%

Valuation

Trailing PE -
Forward PE 138.89
Enterprise Value 454.13M
Price to Sales(TTM) 1.75
Enterprise Value 454.13M
Price to Sales(TTM) 1.75
Enterprise Value to Revenue 1.7
Enterprise Value to EBITDA 145.26
Shares Outstanding 89.32M
Shares Floating 58.75M
Shares Outstanding 89.32M
Shares Floating 58.75M
Percent Insiders 14.28
Percent Institutions 74.86

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.